HCW Biologics (NASDAQ:HCWB – Get Free Report) and Emergent Biosolutions (NYSE:EBS – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.
Analyst Ratings
This is a summary of recent recommendations and price targets for HCW Biologics and Emergent Biosolutions, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
| Emergent Biosolutions | 2 | 1 | 3 | 0 | 2.17 |
HCW Biologics currently has a consensus price target of $30.00, indicating a potential upside of 1,454.40%. Emergent Biosolutions has a consensus price target of $10.00, indicating a potential upside of 47.17%. Given HCW Biologics’ higher possible upside, analysts clearly believe HCW Biologics is more favorable than Emergent Biosolutions.
Insider & Institutional Ownership
Risk and Volatility
HCW Biologics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, Emergent Biosolutions has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500.
Profitability
This table compares HCW Biologics and Emergent Biosolutions’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| HCW Biologics | -83.03% | -262.33% | -34.90% |
| Emergent Biosolutions | -22.95% | 16.35% | 6.17% |
Valuation & Earnings
This table compares HCW Biologics and Emergent Biosolutions”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| HCW Biologics | $50,000.00 | 71.02 | -$7.96 million | ($27.60) | -0.07 |
| Emergent Biosolutions | $742.90 million | 0.47 | $52.60 million | ($3.55) | -1.91 |
Emergent Biosolutions has higher revenue and earnings than HCW Biologics. Emergent Biosolutions is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Summary
Emergent Biosolutions beats HCW Biologics on 9 of the 14 factors compared between the two stocks.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
About Emergent Biosolutions
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
